ZNF331 Inhibitors
Chemical inhibitors of ZNF331 can act through various molecular pathways to inhibit its function. Wortmannin and LY294002 are inhibitors of phosphoinositide 3-kinases (PI3K), a group of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, and survival. The inhibition of PI3K by these chemicals can lead to a decrease in the functional activity of ZNF331 by preventing the activation of downstream signaling molecules that may be necessary for its proper function. Similarly, PD98059 and U0126 target the MAP kinase kinase (MEK) within the MAPK/ERK pathway, a critical pathway that can modulate the activity of various proteins, including ZNF331. The inhibition of MEK by these compounds can result in a reduced activation of ZNF331, impacting its role in cellular processes.
Furthermore, SB203580 and SP600125 inhibit p38 MAP kinase and c-Jun N-terminal kinase (JNK), respectively. Inhibition of p38 MAP kinase by SB203580 can affect stress and inflammation signaling pathways, which can indirectly inhibit the functional activity of ZNF331. SP600125's inhibition of JNK can disrupt cellular processes that are regulated by signaling pathways involving ZNF331. Another compound, Rapamycin, inhibits the mammalian target of rapamycin (mTOR), a central regulator of cell growth. By blocking mTOR, Rapamycin can disrupt downstream signaling required for ZNF331's activity. Dasatinib, a tyrosine kinase inhibitor, can inhibit the phosphorylation of ZNF331, leading to a reduction in its functional activity. Staurosporine, known for its broad kinase inhibition, can prevent the activation of kinases responsible for the phosphorylation of ZNF331, while Bortezomib, a proteasome inhibitor, can lead to the accumulation of ubiquitinated proteins that regulate ZNF331, thereby inhibiting its function. Chelerythrine, by inhibiting protein kinase C (PKC), can affect signaling pathways that regulate ZNF331's function, and H-89, by inhibiting protein kinase A (PKA), can disrupt pathways crucial for the activity of ZNF331.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators in various signaling pathways, including those that may control the activity or function of ZNF331. By inhibiting PI3K, it can lead to the functional inhibition of ZNF331. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K, which is involved in several signaling pathways. By inhibiting PI3K, LY294002 can reduce the phosphorylation and activation of downstream effectors that may be necessary for the functional activity of ZNF331. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the MAP kinase kinase (MEK), which is part of the MAPK/ERK pathway. This pathway can influence the function of various proteins, including ZNF331. Inhibition of MEK can therefore lead to decreased activation of ZNF331. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also inhibits MEK, thereby potentially reducing the activity of the MAPK/ERK pathway. Given the role of this pathway in regulating numerous protein functions, inhibition by U0126 could decrease ZNF331's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is involved in the response to stress and inflammation. Inhibiting p38 MAP kinase can impact signaling pathways that may indirectly inhibit the functional activity of ZNF331. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in the regulation of a variety of cellular processes. Inhibition of JNK can lead to a disruption of signaling pathways that may be required for ZNF331 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a central cell growth regulator. By inhibiting mTOR, Rapamycin may disrupt downstream signaling that could be critical for the functional activity of ZNF331. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that may inhibit kinases which phosphorylate ZNF331, thereby inhibiting its function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor and could inhibit kinases involved in the phosphorylation and thus functional activation of ZNF331. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, potentially including those that regulate the function of ZNF331, leading to its functional inhibition. | ||||||